ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02051218
Recruitment Status : Recruiting
First Posted : January 31, 2014
Last Update Posted : November 20, 2018
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2019
  Estimated Study Completion Date : December 2022